AFT Pharmaceuticals expects to break even this year despite launch delays

Rebecca Howard
Thu, 02 Aug 2018

By Rebecca Howard Aug. 3 (BusinessDesk) -  AFT Pharmaceuticals, which makes the Maxigesic painkiller, continues to target reaching breakeven by the end of this financial year regardless of whether it obtains any additional licensing income.  In the last financial year to the end of March, its loss narrowed to $12.7 million from $18.4 million, Chair David Flacks told shareholders at the annual general meeting in Auckland today that Maxigesic is now licensed in 125 countries – up from 110 at the end of its 2017 financial year – and the c...

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

The Quiz FREE
QuiznessDesk, Tuesday, July 05, 2022
The Quizmaster | Tue, 05 Jul 2022

Don't forget to give our daily quiz a go. Good luck

Law & Regulation
Juice magnate Lepionka sues lawyers for 'negligent' advice
Greg Hurrell | Tue, 05 Jul 2022

Businessman Stefan Lepionka's negligence case against Gibson Sheat will be split in two, with the law firm's countersuit to be heard first, the high court has ruled.

Property
George Kerr's Pyne Gould receivership continues
Victoria Young | Tue, 05 Jul 2022

Court action continues in the UK, while receivers have already clawed back $8m for the BNZ by selling South Island land.

Sponsored
How can Kiwi small business owners manage rising inflation?

Xero MD Craig Hudson says small businesses have been hit with a triple whammy.

Sponsored
Digital innovation could shape the future of NZ

The digital age allows us to collaborate on some of our greatest scientific and environmental challenges